Preview
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
EXHIBIT 9
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
EXHIBIT A
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
7 April 2022
Curriculum Vitae
David Weill, M.D.
Current Position
Title: Principal, Weill Consulting Group
Work Address: 8616 Oak Street, Suite 101, New Orleans, LA 70118
Telephone (office): (504) 558-4942
E-Mail: david@weillconsulting.com
License No: C52127 (CA); ME 130463 (FL); 304283 (LA)
Place of Birth: New Orleans, LA
Citizenship: U.S.
Marital Status: Married
Undergraduate Education:
1985 Bachelor of Arts, Political Science, Tulane University, New Orleans, LA
Cum Laude
Graduate Education:
1990 M.D., Tulane University Medical School
Postdoctoral Training:
06/90-06/93 Internship and Residency in Internal Medicine, Parkland Hospital,
University of Texas-Southwestern
07/93-06/96 Fellowship in Pulmonary and Critical Care Medicine and Lung
Transplantation, University of Colorado at Denver and Health Sciences
Center (UCDHSC)
Honors and Awards:
2019 The Grace Rose Foundation, Medical Professional of the Year
2010 Cystic Fibrosis Research Institute, Professional of the Year
Licensure and Certification:
1993-2003 American Board of Internal Medicine, Internal Medicine
1996 Diplomate in Pulmonary Disease (recertified until 2026)
2006 Diplomate in Critical Care Medicine
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
Grants:
Present/Pending:
2011-2014 National Institutes of Health, RC4, RFA-OD-10-005
Genome Transplant: A non-invasive sequencing-based method for
detecting acute and chronic rejection of solid organ transplants
Co-investigator, 5% effort (Principal Investigators: Hannah
Valantine/Steve Quake)
2011-2013 National Institutes of Health, Program Project Grant
Elafin Therapy of Lung Disease
Co-investigator (Principal Investigator: Marlene Rabinovitch)
2010-2012 National Institutes of Health, NHLBI, R34RFA-HL-10-016
Antibody-mediated rejection in lung transplantation
Principal investigator, 2.5% effort
2008-2012 APT Pharmaceuticals, Inc., CIS001
The goal of this study is to assess the effectiveness of inhaled cyclosporine
in preventing chronic rejection following lung transplantation.
Dr. Weill is the site Principal Investigator
5% effort, $ 275,351 direct costs/yr
A multi-center, randomized, double-blind, placebo-controlled study to
demonstrate the efficacy and safety of cyclosporine inhalation solution
(CIS) in improving bronchiolitis obliterans syndrome-free survival
following lung transplantation
2009-2011 Translational Therapeutics Development Center
Cystic Fibrosis Foundation Therapeutics, Inc MILLA09Y0
Dr. Weill is the Co-Principal Investigator
(Principal Investigator: Carlos Milla)
The major goal of this project is to establish infrastructure support for a
clinical trials network related to cystic fibrosis.
2|P a g e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
2008-2011 Program for Adult Care Excellence
Cystic Fibrosis Foundation, WEILL08ACO
Dr. Weill is the Principal Investigator
The major goal of this project is to enhance the training of adult
physicians in the care of adult patients with cystic fibrosis.
2007-2011 National Institutes of Health
A Multi center Prospective Cohort Study Examining the Role of Protein C
in Early ARDS
Co-investigator (Principal Investigator: Ann Weinacker)
Goal: Participate in a multicenter trial examining primary graft injury
after lung transplantation
Responsibilities: Coordinate patient selection and monitoring with the PI
2010-2011 Cystic Fibrosis Center Grant
Cystic Fibrosis Foundation C011-09
Dr. Weill is the Co-Principal Investigator (Principal Investigator: Carlos
Milla)
The major goal of this project is to provide infrastructure support to the
Stanford Cystic Fibrosis Center.
Appointments:
Professional:
07/96-11/99 Medical Director, Lung and Heart – Lung Transplant Program
Medical City Hospital
Dallas, TX
Academic:
01/2021-present Professor of Medicine
Tulane University Medical School
04/2017-06/2019 Professor of Medicine and Surgery
Morsani College of Medicine
University of South Florida Health
08/01/11-07/01/16 Professor of Medicine
Stanford University School of Medicine
05/01/06-07/31/11 Associate Professor of Medicine
Medical Director, Lung and Heart – Lung Transplant Program
Stanford University School of Medicine
12/31/05-04/30/06 Acting Associate Professor
Stanford University School of Medicine
06/02-11/05 Associate Professor of Medicine
Associate Director, Lung and Heart – Lung Transplant Program
3|Pa ge
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
University of Colorado Health Sciences Center
12/99-05/02 Associate Professor of Medicine
Medical Director, Lung and Heart – Lung Transplant Program
University of Alabama – Birmingham
Other Appointments:
06/17-06/19 Executive Advisor, Tampa Transplant Institute at Tampa General Hospital
Tampa General Hospital/University of South Florida Health
12/05-10/15 Director, Center for Advanced Lung Diseases
Medical Director, Lung and Heart-Lung Transplant Program, Stanford
University Medical Center
09/08-07/13 Director, Adult Cystic Fibrosis Program, Stanford University School of
Medicine
Editorial Board Memberships:
1999-2009 Associate Editor, The Journal of Heart and Lung Transplantation
2018-2019 Editor, Pulse Newsletter, International Society of Heart and Lung
Transplantation
2017-2018 Managing Guest Editor, Special Issue, The Monticello Workshop on
Elongate Mineral Particles, Toxicology and Applied Pharmacology
Peer Review Activities:
2017- Present Toxicology and Applied Pharmacology
2014- Present American Journal of Respiratory and Critical Care Medicine
2014- Present Journal of Toxicology and Environmental Health
2014- Present Thorax
2014- Present Critical Reviews in Toxicology
2013- Present The New England Journal of Medicine
1996- Present The Journal of Heart and Lung Transplantation
1996- Present American Journal of Transplantation
1996- Present The Journal of Chronic Obstructive Pulmonary Disease
1996- Present Chest
1996- Present Clinical Transplantation
Major Committee and Service Responsibilities (Administration)
Divisional:
2007- 2008 Search Committee, Director, Adult Cystic Fibrosis Program, Stanford
2004- 2005 Finance Committee, Division of Pulmonary and Critical Care, University
of Colorado Health Sciences Center
4|P ag e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
Departmental:
2010- 2012 Strategic Planning Committee, Department of Medicine, Stanford
SOM:
2008-Present Quality Council (Co-Chair), Transplantation PPEC, Stanford
2013-2015 Search Committee Chair, Surgical Director, Lung Transplantation,
Cardiothoracic Surgery, Stanford
2010-2012 Faculty Fellow, Stanford
2008-2011 Quality Council, Cardiothoracic Surgery, Stanford
2006-2007 Search Committee, Head, Thoracic Surgery, Cardiothoracic Surgery,
Stanford
2007 Hand Hygiene Physician Task Force, Stanford
2006 Search Committee, Pediatric Pulmonary Biology Center Faculty Member,
Stanford
2002- 2005 Antimicrobial Subcommittee, Pharmacy and Therapeutics Committee,
University of Colorado Health Sciences Center
Leadership Roles:
2009-2015 Director, Center for Advanced Lung Disease, Stanford University Medical
Center
2005-2015 Medical Director, Lung and Heart – Lung Transplant Program, Stanford
University Medical Center
2008-2013 Director, Adult Cystic Fibrosis Center, Stanford University Medical
Center
Professional Society
Leadership Roles:
2019-2021 Member, Working Group, Recipient Selection Consensus Document,
ISHLT
2008-2016 Member, Medical Advisory Board, California Transplant Donor Network
2014-2016 Past Chair, Pulmonary Transplantation Council, International Society of
Heart and Lung Transplantation
2012-2014 Chair, Pulmonary Transplantation Council, International Society of Heart
and Lung Transplantation
2014-2015 Section Editor, ISHLT’s reference guide for the work-up and diagnosis of
common syndromes in thoracic organ transplant recipients
2009-2011 Vice-Chair, Pulmonary Transplantation Council, International Society of
Heart and Lung Transplantation
2008-2011 Pulmonary Council Leader, Standard and Guidelines Committee,
International Society of Heart and Lung Transplantation
5|Pa ge
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
Meeting Session
Chairman
Novel Mechanisms in Chronic Lung Allograft Dysfunction, International
Society of Heart and Lung Transplantation, April 7, 2017
Advances in Immunosuppression, International Society of Heart and Lung
Transplantation, San Diego, April 14, 2014
ISHLT Academy: Core Competencies in Lung Transplantation,
International Society of Heart and Lung Transplantation, San Diego, April
13, 2011
The Lung Allocation System, International Society of Heart and Lung
Transplantation, Paris, April 23, 2009
Advances in Immunosuppression, International Society of Heart and Lung
Transplantation, San Francisco, April 27, 2009
Controversies in Cardiothoracic Transplantation, Cardiothoracic
Transplantation: An International Update, Vail, CO, February 22, 2003
Clinical Lung Transplantation, International Society for Heart and Lung
Transplantation, Osaka, Japan, April 6, 2000
Committee:
2017 Committee Member, Identifying Collaborative Clinical Research Priorities
in Lung Transplantation, National Heart, Lung, and Blood Institute/AATS
2007- Present Abstract Reviewer, International Meeting, International Society of Heart
and Lung Transplantation
2014-2016 Member, Thoracic Committee, United Network for Organ Sharing
2008- 2010 Member, Communications Committee, International Society of Heart and
Lung Transplantation
2006-2008 Member, Membership and Professional Standards Committee, United
Network for Organ Sharing
2005-2006 Member, National Lung Review Board, United Network for Organ
Sharing
2003 Member, Working Group on Primary Lung Graft Failure, International
Society of Heart and Lung Transplantation
2001 Member, Maximizing Cadaveric Organ Utilization, American Society of
Transplantation
Teaching Record:
Curriculum Development:
Lung Transplant Fellowship
Stanford University Medical Center
2005-2015
Lung Transplant Fellowship
University of Colorado Health Sciences Center
2002-2005
6|P ag e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
Lung Transplant Fellowship
University of Alabama – Birmingham
1999-2002
Governmental Consulting:
United States Senate
Environment and Public Works
The Heath Effects of Asbestos
June 2007
United States Senate
Judiciary Committee Testimony
Asbestos and Mixed Dust Disease
February 2005
Texas State Legislature Testimony
House Bill 8 Regarding Asbestos and Silica
March 2005
Scientific Consulting:
Chair, Scientific Advisory Board
National Stone, Sand, and Gravel Association
2012-present
Member, Scientific Advisory Board
GlycosBio
2018-present
Member, Scientific Advisory Board
Kallaco
2020-present
Member, Strategic Advisory Board
ZEPHYRx
2021-present
Advisory Councils:
Member, The Center for Entrepreneurship
Wake Forest University
2020-present
7|Page
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
Publications:
Peer-Reviewed Articles
1. Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV,
Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff
RM, Patterson CM, Shlobin OA, Smith PJ, Solé A, Solomon M, Weill D, Wijsenbeek
MS, Willemse BWM, Arcasoy SM, Ramos KJ. Consensus document for the selection of
lung transplant candidates: An update from the International Society for Heart and Lung
Transplantation. J Heart Lung Transplant. 2021 Nov;40(11):1349-1379.
2. Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, Shullo M,
Schweiger M, Weill D, Stuckey L, Ivulich S, Scheel J, Peters L, Colvin M, Dawson K,
Girgis R, Weeks P, Tse T, Russell S, Flattery M, Jennings D, Kittleson M, Miller T,
Khuu T, Claridge T, Uber P, Ford K, Ensor CR, Simpson K, Dipchand A, Page RL 2nd..
Report from the 2018 consensus conference on immunomodulating agents in thoracic
transplantation: Access, formulations, generics, therapeutic drug monitoring, and special
populations J Heart Lung Transplant. 2020 Oct;39(10):1050-1069
3. Sethi, JS, Bugajski A, Patel KN, Davis NM, Wille KM, Qureshi MR, Banday MM, Lin
M, Emani V, Weill D, Tumin D, Hayes D, Sharma N. Recipient Age Impacts Long-
Term Survival in Adult Cystic Fibrosis Subjects after Lung Transplantation.
ANNALSATS 2020, Aug 14
4. Kheir F, Alkhatib A, Berry GJ, Daroca P, Diethelm L, Rampolla R, Saito S, Smith
DL, Weill D, Bateman M, Abdelghani R, Lasky JA. Employing Bronchoscopic Lung
Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse
Interstitial Lung Diseases Chest. 2020 May 25:S0012-3692(20)31499-9
5. Weill D. Proceedings of the Monticello Conference on Elongate Mineral Particles.
Toxicol Appl Pharmacol 2018 Dec 15;361:1-2
6. National Heart, Lung, and Blood Institute and American Association of Thoracic
Surgery Workshop: Identifying Collaborative Clinical Research Priorities in lung
transplantation. Mulligan MS, Weill D, Davis RD, Christie JD, Farjah F, Singer JP,
Hartwig M, Sanchez PG, Kreisel D, Ware LB, Bermudez C, Hachem RR, Weyant MJ,
Gries C, Awori Hayanga JW, Griffith BP, Snyder LD, Odim J, Craig JM, Aggarwal NR,
Reineck LA. J Thorac Cardiovasc Surg 2018 Aug 18. pii: S0022-5223(18)32135-4
7. Weill D. Lung transplantation: indications and contraindications. J Thorac Dis
2018;10(7):4574-4587
8. Hachem RR, Kamoun M, Budev MM, Askar M, Ahya VN, Lee JC, Levine DJ, Pollack
MS, Dhillon GS, Weill D, Schechtman KB, Leard LE, Golden JA, Baxter-Lowe L,
Mohanakumar T, Tyan DB, Yusen RD. Human leukocyte antibodies after lung
transplantation: Primary Results of the HALT Study. Am J Transplant. 2018 Apr 24
9. Snell GI, Yusen RD, Weill D, Strueber M, Garrity E, Reed A, Pelaez A, Whelan TP,
Perch M, Bag R, Budev M, Corris PA, Crespo MM, Witt C, Cantu E, Christie JD.
Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I:
Definition and Grading – A 2016 Consensus group statement of the International
Society for the Heart and Lung Transplantation J Heart Lung Transplant. 2017
Oct;36(10):1097-1103
8|P a ge
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
10. Cantu E, Diamond JM, Suzuki Y, Lasky J, Schaufler C, Lim B, Shah R, Porteous M,
Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade S,
Bermudez C, Crespo M, McDyer J, Wille K, Orens J, Shah PD, Weinacker A, Weill D,
Wilkes D, Roe D, Hage C, Ware LB, Bellamy SL, Christie JD; Lung Transplant
Outcomes Group. Am J Respir Crit Care Med. 2017 Sep 5
11. Pasupneti S, Patel K, Mooney JJ, Chhatwani L, Dhillon G, Weill D. Lung
transplantation following death by drowning: a review of the current literature. Clin
Transplant. 2016 Oct
12. Mooney JJ, Weill D, Boyd JH, Nicolls MR, Bhattacharya J, Dhillon GS. Effect of
Transplant Center Volume on Cost and Readmissions in Medicare Lung Transplant
Recipients. Ann Am Thorac Soc. 2016 Apr 11
13. Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL.
Addressing inherited predisposition for breast cancer in transplant recipients. J Surg
Oncol. 2016 Feb
14. Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL.
Addressing inherited predisposition for breast cancer in transplant recipients. J Surg
Oncol. 2016 Feb.
15. Cantu E, Suzuki Y, Diamond JM, Ellis J, Tiwari J, Beduhn B, Nellen JR, Shah R, Meyer
NJ, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade
S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Wilkes D,
Roe D, Ware LB, Wang F, Feng R, Christie JD. Lung Transplant Outcomes Group.
Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate
Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.
Am J Transplant. 2015 Dec.
16. Hill C, Maxwell B, Boulate D, Haddad F, Ha R, Afshar K, Weill D, Dhillon GS. Heart-
lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. Clin
Transplant. 2015 Dec;29(12):1067-75.
17. Iwijn De Vlaminck, Lance Martina, Michael Kertesza, Kapil Patel, Mark Kowarskya,
Calvin Strehle, Garrett Cohene, Helen Luikart, Norma F. Neff, Jennifer Okamoto, Mark
R. Nicolls, David Cornfield, Weill D, Hannah Valantine, Kiran K. Khush, and Stephen
R. Quake. Noninvasive monitoring of infection and rejection after lung transplantation.
PNAS. 2015 Oct;112(43):13336-41.
18. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan
MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A
consensus document for the selection of lung transplant candidates: 2014 – an update
from the Pulmonary Transplantation Council of the International Society for Heart and
Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15.
19. Maxwell BG, Mooney JJ, Lee PH, Levitt JE, Chhatwani L, Nicolls MR, Zamora MR,
Valentine V, Weill D, Dhillon GS. Increased resource utilization in lung transplant
admissions in the Lung Allocation Score era. Am J Respir Crit Care Med. 2014 Dec 17.
20. Maxwell BG, Levitt JE, Goldstein BA, Mooney JJ, Nicolls MR, Zamora M, Valentine
V, Weill D, Dhillon GS. Impact of the lung allocation score on survival beyond 1 year.
Am J Transplant. 2014 Oct;14(10):2288-94.
21. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder
TM, Cornfield DN, Nicolls MR, Weill D, Bernstein D, Valantine HA, Quake SR.
Temporal response of the human virome to immunosuppression and antiviral therapy.
Cell 2013 Nov 21;155(5):1178-87.
9|P ag e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
22. Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee
J, Bellamy SL, Palmer SM, Lama VN, Bhorade SM, Crespo M, Demissie E, Wille K,
Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD;
Lung Transplant Outcomes Group. Elevated plasma angiopoietin-2 levels and primary
graft dysfunction after lung transplantation. PLoS One 2012;7(12):e51932.
23. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu
E, Shah RJ, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J,
Weinacker A, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer
SM, Christie JD. Variation in PTX3 is associated with primary graft dysfunction after
lung transplantation. Am J Respi Crit Care Med 2012 Sep 15;186(6):546-52.
24. Dhillon G, Valentine V, Levitt J, Gupta M, Duncan S, Seoane L, and Weill D.
Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft
recipients. Clinical Transplantation. 2012 Jan-Feb;26(1):105-10.
25. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama
VN, Bhorade S, Crespo M, Demissie E, Sonnett J, Wille K, Orens J, Sha PD, Weinacker
A, Weill D, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belpierio JA, Wilkes D,
Reynolds JM, Ware LB, Christie JD. Elevated plasma long pentraxin-3 levels and
primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.
Am J Transplant 2011 Nov;11(11):2517-22.
26. Liu V, Weill D., Bhattacharya J. Racial Disparities in Survival After Lung
Transplantation. Arch Surg 2011 Mar;146(3):286-93.
27. Liu V, Bhattacharya J, Weill D, Hunt S, and Hlatky MA. Persistent racial disparities in
survival following heart transplantation. Circulation 2011 Apr 19;123(15):1642-9. My
primary role in this study was to provide significant editing to the manuscript. I also
took the primary responsibility for answering the reviewers’ questions.
28. Weill D, Dhillon G, Freyder L, Lefante J, and Glindmeyer H. Lung function, radiologic
changes, and exposure: analysis of ATSDR data from Libby, Montana. European
Respiratory Journal 2011 Aug;38(2):376-83.
29. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, van der Starre P, Weill D,
Nicolls MR. Lung transplant airway hypoxia: a diathesis to fibrosis. Am J Respir Crit
Care Med. 2010 Jul 15;182(2):230-6. My primary role in this study was to provide
significant editing to the manuscript. I also took the primary responsibility for
answering the reviewers’ questions.
30. Deuse T, Sista R, Weill D, Haddad F, Dhillon G, Robbins RC, and Reitz BA. Review
of heart-lung transplantation at Stanford. Ann Thorac Surg 2010 Jul; 90(1):329-37. My
primary role in this study was to provide significant editing to the manuscript. I also
took the primary responsibility for answering the reviewers’ questions.
31. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, and Rosen GD. SPARC
suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive
activation of beta-catenin. J Biol Chem. 2010 Mar 12;285(11):8196-206. My role in
this study was to take the primary role in collecting the clinical data for analysis. My
secondary role was to heavily edit the manuscript.
32. Liu V, Zamora MR, Dhillon GS, and Weill D. Increasing Lung Allocation Scores
Predict Worsened Survival among Lung Transplant Recipients. American Journal of
Transplantation 2010 Apr;10(4):915-20.
33. Liu V, Dhillon GS, and Weill D. A multi-drug regimen for respiratory syncytial virus
and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
Transpl Infect Dis 2010 Feb;12(1):38-44.
10 | P a g e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
34. Choi JY, Khansaheb M, Joo NS, Krouse ME, Robbins RC, Weill D, and Wine JJ.
Substance P stimulates airway submucosal gland secretion mainly via a CFTR –
dependent process. Journal of Clinical Investigation 2009 May;119(5):1189-200. My
role in this study was to take the primary role in collecting the clinical data for analysis.
My secondary role was to heavily edit the manuscript.
35. Valentine VG, Weill D, Lombard GA, LaPlace SG, Seoane L, Taylor DE, Dhillon GS.
A Single Institution Study Evaluating the Utility of Surveillance Bronchoscopy
Following Lung Transplantation. Journal of Heart and Lung Transplantation 2009
Jan;28(1):14-20. My primary role in this study was to provide significant editing to the
manuscript. I also took the primary responsibility for answering the reviewers’
questions.
36. Dhillon GS, Levitt J, Mallidi H, Valentine VG, Gupta MR, Sista R, and Weill D. Impact
of Hepatitis B core antibody positive donors in lung and heart-lung transplantation: an
analysis of the United Network for Organ Sharing database. Transplantation 2009;
88:842-846.
37. Valentine VG, Weill D, Raper B, Lombard GA, LaPlace SG, Bonvillain RW, Seoane L,
Taylor DE, Dhillon GS. Ganciclovir for Cytomegalovirus: A Call for Indefinite
Prophylaxis in Lung Transplantation. Journal of Heart and Lung Transplantation 2008
Aug;27(8):875-81. My primary role in this study was to provide significant editing to
the manuscript. I also took the primary responsibility for answering the reviewers’
questions.
38. Leung M, Rachakonda L, Weill D, and Hwang P. Outcomes of Sinus Surgery before
Lung Transplantation for Cystic Fibrosis. American Journal of Rhinology 2008 Mar –
Apr; 22(2): 192 – 6. My role in this study was to take the primary role in collecting the
clinical data for analysis. My secondary role was to heavily edit the manuscript.
39. Mulligan MS, Shearon TH, Weill D, Pagani FD, Moore J, and Murray S. Heart and
Lung Transplantation in the United States, 1997-2006. American Journal of
Transplantation 2008 Apr; 8(4 Pt 2):977-87. My primary role in this study was to
provide significant editing to the manuscript. I also took the primary responsibility for
answering the reviewers’ questions.
40. Astor TL, Weill D, Cool C, Teitlebaum I, Schwarz MI and Zamora MR. Pulmonary
capillaritis in lung transplant recipients: treatment and effect on allograft function.
Journal of Heart and Lung Transplantation 2005; 24:2091-7. My primary role in this
study was to provide significant editing to the manuscript. I also took the primary
responsibility for answering the reviewers’ questions.
41. Christie JD, Carby M, Bag R, Corris P, Hertz M, and Weill D. Report of the ISHLT
Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus
Statement of the International Society for Heart and Lung Transplantation. Journal of
Heart and Lung Transplantation 2005 Oct; 24(10):1454-9.
42. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor TL, Grazia T, and Weill D.
Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus
Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection
Following Lung Transplantation. American Journal of Transplantation 2004 Oct;
4(10):1635-42.
43. Dransfield MT, Garver RI, and Weill D. Standardized guidelines for surveillance
bronchoscopy reduce complications in lung transplant recipients. Journal of Heart and
Lung Transplantation 2004; 23(1):110-4.
44. Zorn GL, McGiffin DC, Young KR, Alexander CB, Weill D, and Kirklin JK.
11 | P a g e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
Pulmonary transplantation for advanced bronchioloalveolar carcinoma. Journal of
Thoracic and Cardiovascular Surgery 2003; 125(1):45-8. My role in this study was to
take the primary role in collecting the clinical data for analysis. My secondary role was
to heavily edit the manuscript.
45. Weill D, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, and
McGifffin DC. Combination prophylaxis with ganciclovir and cytomegalovirus immune
globulin after lung transplantation: Effective CMV prevention following daclizumab
induction. American Journal of Transplantation 2003; 3(4):492-496.
46. Weill D, Dey GC, Hicks RA, Young KR, Zorn GL, Kirklin JK, Early L, and McGiffin
DC. A positive donor gram stain does not predict outcome following lung
transplantation. Journal of Heart and Lung Transplantation 2002; 21(5):555-8.
47. Schmidt F, McGiffin DC, Zorn G, Young KY, Weill D, and Kirklin JK. Management
of congenital abnormalities of the donor lung. Annals of Thoracic Surgery 2001;
72(3):935-7. My role in this study was to take the primary role in collecting the clinical
data for analysis. My secondary role was to heavily edit the manuscript.
48. Nemunaitis J, Swisher SG, Mack M, Weill D, Merritt J, and Roth J. Adenovirus-
mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-
small cell lung cancer. Journal of Clinical Oncology 2000; 18(3):609-622. My role in
this study was to take the primary role in collecting the clinical data for analysis. My
secondary role was to heavily edit the manuscript.
49. Weill D, Mack MJ, Roth J, Swisher S, Proksch, Merritt J, and Nemunaitis J.
Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through
endobronchial injection. Chest 2000; 118:966-70.
50. Weill D, McGiffin DC, Zorn GL, Alexander CB, Early LJ, Kirklin JK, and Young KR.
The utility of open lung biopsy following lung transplantation. Journal of Heart and
Lung Transplantation 2000; 19(9):852-857.
51. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors
DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ,
Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM,
Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J,
Weill D, and Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-
small-cell lung cancer. J Natl Cancer Inst. 1999 May 5; 91(9):763-71. My role in this
study was to take the primary role in collecting the clinical data for analysis. My
secondary role was to heavily edit the manuscript.
52. Weill D, Hodges TN, Torres F, and Zamora MR. Acute native lung hyperinflation is
not associated with a poor outcome following single lung transplantation for
emphysema. Journal of Heart and Lung Transplantation 1999; 18:1080-1087.
53. Badesch DB, Zamora MR, Weill D, and Schwarz MI. Pulmonary capillaritis: a possible
histologic form of acute allograft rejection. Journal of Heart and Lung Transplantation
1998; 17(4):415-422. My role in this study was to take the primary role in collecting the
clinical data for analysis. My secondary role was to heavily edit the manuscript.
54. Terada LS, Hybertson BM, Weill D, and Repine JE. XO increases neutrophil adherence
to endothelial cells by a dual mechanism. Journal of Applied Physiology 1997;
82(3):866-873. My role is this study was to provide technical support in the
experimental model for the more senior researchers. My secondary role was to write
the sections regarding the scientific methodology.
55. Beaver TM, Fullerton DA, Weill D, and Grover FL. Colon perforation after lung
12 | P a g e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
transplantation. Annals of Thoracic Surgery 1996; 62:839-843. My role in this study
was to take the primary role in collecting the clinical data for analysis. My secondary
role was to heavily edit the manuscript.
56. Leard Lorriana, Holm Are, Valapour Maryam, Glanville Allan, Attawar Sandeep,
Aversa Meghan, Campos Silvia, Christon Lillian, Cypel Marcelo, Dellgren Goran,
Hartwig Matthew, Kapnadak Siddhartha, Kolaitis Nicholas, Kotloff Robert, Patterson
Caroline, Shlobin Oksana, Smith Patrick, Sole Amparo, Solomon Melinda, Weill D,
Wijsenbeek Marlies, Willemse Brigitte, Arcasoy Selim, Ramos Kathleen. Consensus
document for the selection of lung transplant candidates: An update from the
International Society for Heart and Lung Transplantation, The Journal of Heart and
Lung Transplantation, Volume 40, Issue 11, P1349-1379. November 1, 2021.
Editorials
1. Weill D. Access to Lung Transplantation: The Long and Short of It. Am J Respir Crit
Care Med. 2016 Mar 15;193(6):605-6.
2. Weill D. Twenty years of lung transplantation: areas of improvements and challenges.
Minerva Pneumologica 2003; 42:139-57.
3. Weill D. Donor criteria in lung transplantation: an issue revisited. Chest 2002; 121:2029-
2031.
4. Weill D and Keshavjee S. Lung Transplantation for Emphysema: Two Lungs or One?
Journal of Heart and Lung Transplantation 2001; 20(7):739-742.
5. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transplant
Infectious Disease 2001 Suppl 2:3:44-48.
Reviews
1. Galbraith D and Weill D. Popcorn Lung and Bronchiolitis Obliterans: A Critical
Appraisal. International Archives and Environmental Health 2008 June 12.
2. Astor TL and Weill D. Extracorporeal photopheresis in lung transplantation. Journal of
Cutaneous Medicine and Surgery 2003 Sep 9.
3. Weill D, Mack MJ, and Tennison D. Adverse effects of medications commonly
administered to thoracic surgical patients. Chest Surgery Clinics of North America,
Medical Complications of Thoracic Surgery, August 1999.
Book Chapters/Monographs
1. Weill D. The history of lung transplantation. The Psychosocial Care of the End-Stage
Disease and Transplant Patients. Editors: Sher and Maldonado, 2018.
2. Weill D. Lung transplantation: indications and contraindications. Lung Transplantation in
the Third Millennium. Editors: Van Raemdonck and Venuta, 2018.
3. Dhillon GS and Weill D. Recipient management before transplantation. Lung
Transplantation: Principles and Practice. Editors: Vigneswaran and Garrity, 2016.
4. Weill D. Asbestos and asbestos-related diseases. Hunter’s Diseases of Occupation, 10th
13 | P a g e
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020
NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023
CURRICULUM VITAE: DAVID WEILL 7 April 2022
Edition, Editors: Baxter, Aw, Cockcroft, Durrington, and Harrington, 2010.
5. Weill D. The Clinical Aspects of the Asbestos Associated Diseases. Asbestos and Its
Diseases, 1st Edition, Editors: Craighead and Gibbs, 2008.
6. Astor TL and Weill D. Oxidative Lung Injury. Textbook of Critical Care, 5th Edition,
Editors: Fink, Abraham, Vincent, Kochanek, 2005.
7. Weill D. Lung Transplantation. Textbook of Critical Care, 5th Edition, Editors: Fink,
Abraham, Vincent, Kochanek, 2005.
8. Weill D, Rose C, and King TE. Treatment and prognosis of hypersensitivity pneumonitis.
UPTODATE in Pulmonary and Critical Care Medicine, 1997, American Thoracic
Society.
9. Weill D and Zamora MR. Postoperative care in lung transplantation. Seminars in
Respiratory Medicine 1996; 17(2):159-165.
10. Weill D and Make B. Oxygen Conserving Devices. Long-Term Oxygen Therapy, New
York: Marcel Dekker, 1994; 234-256.
Letters
1. Weill D, Chatfield E, Cox A Jr, Gamble J, Gibbs G, Wylie A. In reference to Hwang et
al. “The Relationship Between Various Exposure Metrics for Elongate Mineral Particles
(EMP) in the Taconite Mining and Processing Industry” J Occup Envir Hyg. 2015 Jan 23.
2. Galbraith DA and Weill D. Authors’ response to Kreiss et al. Int Arch Occup Environ
Health 2010 Feb;83(2):237-40.
3. Finley BL, Galbraith DA, and Weill D. Comments on respiratory toxicity of diacetyl.
Toxicol SCi 2008 Oct;105(2):429-32.
4. Galbraith DA and Weill D. Diacetyl and bronchiolitis obliterans. Am J Respir Crit Care
Med 2008 Aug 1;178(3):313.
5. Weill D and Weill H. Diagnosis and initial management of nonmalignant diseases related
to asbestos. Am J Respir Crit Care Med. 2005 Mar 1; 171(5):527-528.
6. Weill D and Zamora MR. Comparison of the efficacy and cost effectiveness of
preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir
in lung transplant recipients. Journal of Heart and Lung Transplantation 2000;
19(8):815-6.
Oral Presentations (competitive)
1. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, Van der Starre P, Weill D, Nicolls
MR. Lung Transplant Airway Hypoxia: A Diathesis to Fibrosis? American Thoracic Society
Annual Meeting, New Orleans, May 2010.
2. Weill D, Young R, and McGiffin DC. A Positive Donor Gram Stain Does Not Predict the
Development of Pneumonia, Oxygenation, or Duration of Mechanical Ventilation Following
Lung Transplantation, International Society of Heart and Lung Transplantation, April, 2001.
3. Weill D, Young R, And McGiffin DC. The Utility of Open Lung Biopsy Following Lung
Transplantation, 4th International Congress on Lung Transplantation, September, 2000.
4. Weill D, Magee M, Dewey T, and Mack MJ. Impact of
Preview
FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 EXHIBIT 9 FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 EXHIBIT A FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 7 April 2022 Curriculum Vitae David Weill, M.D. Current Position Title: Principal, Weill Consulting Group Work Address: 8616 Oak Street, Suite 101, New Orleans, LA 70118 Telephone (office): (504) 558-4942 E-Mail: david@weillconsulting.com License No: C52127 (CA); ME 130463 (FL); 304283 (LA) Place of Birth: New Orleans, LA Citizenship: U.S. Marital Status: Married Undergraduate Education: 1985 Bachelor of Arts, Political Science, Tulane University, New Orleans, LA Cum Laude Graduate Education: 1990 M.D., Tulane University Medical School Postdoctoral Training: 06/90-06/93 Internship and Residency in Internal Medicine, Parkland Hospital, University of Texas-Southwestern 07/93-06/96 Fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation, University of Colorado at Denver and Health Sciences Center (UCDHSC) Honors and Awards: 2019 The Grace Rose Foundation, Medical Professional of the Year 2010 Cystic Fibrosis Research Institute, Professional of the Year Licensure and Certification: 1993-2003 American Board of Internal Medicine, Internal Medicine 1996 Diplomate in Pulmonary Disease (recertified until 2026) 2006 Diplomate in Critical Care Medicine FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 Grants: Present/Pending: 2011-2014 National Institutes of Health, RC4, RFA-OD-10-005 Genome Transplant: A non-invasive sequencing-based method for detecting acute and chronic rejection of solid organ transplants Co-investigator, 5% effort (Principal Investigators: Hannah Valantine/Steve Quake) 2011-2013 National Institutes of Health, Program Project Grant Elafin Therapy of Lung Disease Co-investigator (Principal Investigator: Marlene Rabinovitch) 2010-2012 National Institutes of Health, NHLBI, R34RFA-HL-10-016 Antibody-mediated rejection in lung transplantation Principal investigator, 2.5% effort 2008-2012 APT Pharmaceuticals, Inc., CIS001 The goal of this study is to assess the effectiveness of inhaled cyclosporine in preventing chronic rejection following lung transplantation. Dr. Weill is the site Principal Investigator 5% effort, $ 275,351 direct costs/yr A multi-center, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of cyclosporine inhalation solution (CIS) in improving bronchiolitis obliterans syndrome-free survival following lung transplantation 2009-2011 Translational Therapeutics Development Center Cystic Fibrosis Foundation Therapeutics, Inc MILLA09Y0 Dr. Weill is the Co-Principal Investigator (Principal Investigator: Carlos Milla) The major goal of this project is to establish infrastructure support for a clinical trials network related to cystic fibrosis. 2|P a g e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 2008-2011 Program for Adult Care Excellence Cystic Fibrosis Foundation, WEILL08ACO Dr. Weill is the Principal Investigator The major goal of this project is to enhance the training of adult physicians in the care of adult patients with cystic fibrosis. 2007-2011 National Institutes of Health A Multi center Prospective Cohort Study Examining the Role of Protein C in Early ARDS Co-investigator (Principal Investigator: Ann Weinacker) Goal: Participate in a multicenter trial examining primary graft injury after lung transplantation Responsibilities: Coordinate patient selection and monitoring with the PI 2010-2011 Cystic Fibrosis Center Grant Cystic Fibrosis Foundation C011-09 Dr. Weill is the Co-Principal Investigator (Principal Investigator: Carlos Milla) The major goal of this project is to provide infrastructure support to the Stanford Cystic Fibrosis Center. Appointments: Professional: 07/96-11/99 Medical Director, Lung and Heart – Lung Transplant Program Medical City Hospital Dallas, TX Academic: 01/2021-present Professor of Medicine Tulane University Medical School 04/2017-06/2019 Professor of Medicine and Surgery Morsani College of Medicine University of South Florida Health 08/01/11-07/01/16 Professor of Medicine Stanford University School of Medicine 05/01/06-07/31/11 Associate Professor of Medicine Medical Director, Lung and Heart – Lung Transplant Program Stanford University School of Medicine 12/31/05-04/30/06 Acting Associate Professor Stanford University School of Medicine 06/02-11/05 Associate Professor of Medicine Associate Director, Lung and Heart – Lung Transplant Program 3|Pa ge FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 University of Colorado Health Sciences Center 12/99-05/02 Associate Professor of Medicine Medical Director, Lung and Heart – Lung Transplant Program University of Alabama – Birmingham Other Appointments: 06/17-06/19 Executive Advisor, Tampa Transplant Institute at Tampa General Hospital Tampa General Hospital/University of South Florida Health 12/05-10/15 Director, Center for Advanced Lung Diseases Medical Director, Lung and Heart-Lung Transplant Program, Stanford University Medical Center 09/08-07/13 Director, Adult Cystic Fibrosis Program, Stanford University School of Medicine Editorial Board Memberships: 1999-2009 Associate Editor, The Journal of Heart and Lung Transplantation 2018-2019 Editor, Pulse Newsletter, International Society of Heart and Lung Transplantation 2017-2018 Managing Guest Editor, Special Issue, The Monticello Workshop on Elongate Mineral Particles, Toxicology and Applied Pharmacology Peer Review Activities: 2017- Present Toxicology and Applied Pharmacology 2014- Present American Journal of Respiratory and Critical Care Medicine 2014- Present Journal of Toxicology and Environmental Health 2014- Present Thorax 2014- Present Critical Reviews in Toxicology 2013- Present The New England Journal of Medicine 1996- Present The Journal of Heart and Lung Transplantation 1996- Present American Journal of Transplantation 1996- Present The Journal of Chronic Obstructive Pulmonary Disease 1996- Present Chest 1996- Present Clinical Transplantation Major Committee and Service Responsibilities (Administration) Divisional: 2007- 2008 Search Committee, Director, Adult Cystic Fibrosis Program, Stanford 2004- 2005 Finance Committee, Division of Pulmonary and Critical Care, University of Colorado Health Sciences Center 4|P ag e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 Departmental: 2010- 2012 Strategic Planning Committee, Department of Medicine, Stanford SOM: 2008-Present Quality Council (Co-Chair), Transplantation PPEC, Stanford 2013-2015 Search Committee Chair, Surgical Director, Lung Transplantation, Cardiothoracic Surgery, Stanford 2010-2012 Faculty Fellow, Stanford 2008-2011 Quality Council, Cardiothoracic Surgery, Stanford 2006-2007 Search Committee, Head, Thoracic Surgery, Cardiothoracic Surgery, Stanford 2007 Hand Hygiene Physician Task Force, Stanford 2006 Search Committee, Pediatric Pulmonary Biology Center Faculty Member, Stanford 2002- 2005 Antimicrobial Subcommittee, Pharmacy and Therapeutics Committee, University of Colorado Health Sciences Center Leadership Roles: 2009-2015 Director, Center for Advanced Lung Disease, Stanford University Medical Center 2005-2015 Medical Director, Lung and Heart – Lung Transplant Program, Stanford University Medical Center 2008-2013 Director, Adult Cystic Fibrosis Center, Stanford University Medical Center Professional Society Leadership Roles: 2019-2021 Member, Working Group, Recipient Selection Consensus Document, ISHLT 2008-2016 Member, Medical Advisory Board, California Transplant Donor Network 2014-2016 Past Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation 2012-2014 Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation 2014-2015 Section Editor, ISHLT’s reference guide for the work-up and diagnosis of common syndromes in thoracic organ transplant recipients 2009-2011 Vice-Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation 2008-2011 Pulmonary Council Leader, Standard and Guidelines Committee, International Society of Heart and Lung Transplantation 5|Pa ge FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 Meeting Session Chairman Novel Mechanisms in Chronic Lung Allograft Dysfunction, International Society of Heart and Lung Transplantation, April 7, 2017 Advances in Immunosuppression, International Society of Heart and Lung Transplantation, San Diego, April 14, 2014 ISHLT Academy: Core Competencies in Lung Transplantation, International Society of Heart and Lung Transplantation, San Diego, April 13, 2011 The Lung Allocation System, International Society of Heart and Lung Transplantation, Paris, April 23, 2009 Advances in Immunosuppression, International Society of Heart and Lung Transplantation, San Francisco, April 27, 2009 Controversies in Cardiothoracic Transplantation, Cardiothoracic Transplantation: An International Update, Vail, CO, February 22, 2003 Clinical Lung Transplantation, International Society for Heart and Lung Transplantation, Osaka, Japan, April 6, 2000 Committee: 2017 Committee Member, Identifying Collaborative Clinical Research Priorities in Lung Transplantation, National Heart, Lung, and Blood Institute/AATS 2007- Present Abstract Reviewer, International Meeting, International Society of Heart and Lung Transplantation 2014-2016 Member, Thoracic Committee, United Network for Organ Sharing 2008- 2010 Member, Communications Committee, International Society of Heart and Lung Transplantation 2006-2008 Member, Membership and Professional Standards Committee, United Network for Organ Sharing 2005-2006 Member, National Lung Review Board, United Network for Organ Sharing 2003 Member, Working Group on Primary Lung Graft Failure, International Society of Heart and Lung Transplantation 2001 Member, Maximizing Cadaveric Organ Utilization, American Society of Transplantation Teaching Record: Curriculum Development: Lung Transplant Fellowship Stanford University Medical Center 2005-2015 Lung Transplant Fellowship University of Colorado Health Sciences Center 2002-2005 6|P ag e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 Lung Transplant Fellowship University of Alabama – Birmingham 1999-2002 Governmental Consulting: United States Senate Environment and Public Works The Heath Effects of Asbestos June 2007 United States Senate Judiciary Committee Testimony Asbestos and Mixed Dust Disease February 2005 Texas State Legislature Testimony House Bill 8 Regarding Asbestos and Silica March 2005 Scientific Consulting: Chair, Scientific Advisory Board National Stone, Sand, and Gravel Association 2012-present Member, Scientific Advisory Board GlycosBio 2018-present Member, Scientific Advisory Board Kallaco 2020-present Member, Strategic Advisory Board ZEPHYRx 2021-present Advisory Councils: Member, The Center for Entrepreneurship Wake Forest University 2020-present 7|Page FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 Publications: Peer-Reviewed Articles 1. Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff RM, Patterson CM, Shlobin OA, Smith PJ, Solé A, Solomon M, Weill D, Wijsenbeek MS, Willemse BWM, Arcasoy SM, Ramos KJ. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021 Nov;40(11):1349-1379. 2. Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, Shullo M, Schweiger M, Weill D, Stuckey L, Ivulich S, Scheel J, Peters L, Colvin M, Dawson K, Girgis R, Weeks P, Tse T, Russell S, Flattery M, Jennings D, Kittleson M, Miller T, Khuu T, Claridge T, Uber P, Ford K, Ensor CR, Simpson K, Dipchand A, Page RL 2nd.. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations J Heart Lung Transplant. 2020 Oct;39(10):1050-1069 3. Sethi, JS, Bugajski A, Patel KN, Davis NM, Wille KM, Qureshi MR, Banday MM, Lin M, Emani V, Weill D, Tumin D, Hayes D, Sharma N. Recipient Age Impacts Long- Term Survival in Adult Cystic Fibrosis Subjects after Lung Transplantation. ANNALSATS 2020, Aug 14 4. Kheir F, Alkhatib A, Berry GJ, Daroca P, Diethelm L, Rampolla R, Saito S, Smith DL, Weill D, Bateman M, Abdelghani R, Lasky JA. Employing Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases Chest. 2020 May 25:S0012-3692(20)31499-9 5. Weill D. Proceedings of the Monticello Conference on Elongate Mineral Particles. Toxicol Appl Pharmacol 2018 Dec 15;361:1-2 6. National Heart, Lung, and Blood Institute and American Association of Thoracic Surgery Workshop: Identifying Collaborative Clinical Research Priorities in lung transplantation. Mulligan MS, Weill D, Davis RD, Christie JD, Farjah F, Singer JP, Hartwig M, Sanchez PG, Kreisel D, Ware LB, Bermudez C, Hachem RR, Weyant MJ, Gries C, Awori Hayanga JW, Griffith BP, Snyder LD, Odim J, Craig JM, Aggarwal NR, Reineck LA. J Thorac Cardiovasc Surg 2018 Aug 18. pii: S0022-5223(18)32135-4 7. Weill D. Lung transplantation: indications and contraindications. J Thorac Dis 2018;10(7):4574-4587 8. Hachem RR, Kamoun M, Budev MM, Askar M, Ahya VN, Lee JC, Levine DJ, Pollack MS, Dhillon GS, Weill D, Schechtman KB, Leard LE, Golden JA, Baxter-Lowe L, Mohanakumar T, Tyan DB, Yusen RD. Human leukocyte antibodies after lung transplantation: Primary Results of the HALT Study. Am J Transplant. 2018 Apr 24 9. Snell GI, Yusen RD, Weill D, Strueber M, Garrity E, Reed A, Pelaez A, Whelan TP, Perch M, Bag R, Budev M, Corris PA, Crespo MM, Witt C, Cantu E, Christie JD. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and Grading – A 2016 Consensus group statement of the International Society for the Heart and Lung Transplantation J Heart Lung Transplant. 2017 Oct;36(10):1097-1103 8|P a ge FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 10. Cantu E, Diamond JM, Suzuki Y, Lasky J, Schaufler C, Lim B, Shah R, Porteous M, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade S, Bermudez C, Crespo M, McDyer J, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Wilkes D, Roe D, Hage C, Ware LB, Bellamy SL, Christie JD; Lung Transplant Outcomes Group. Am J Respir Crit Care Med. 2017 Sep 5 11. Pasupneti S, Patel K, Mooney JJ, Chhatwani L, Dhillon G, Weill D. Lung transplantation following death by drowning: a review of the current literature. Clin Transplant. 2016 Oct 12. Mooney JJ, Weill D, Boyd JH, Nicolls MR, Bhattacharya J, Dhillon GS. Effect of Transplant Center Volume on Cost and Readmissions in Medicare Lung Transplant Recipients. Ann Am Thorac Soc. 2016 Apr 11 13. Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. J Surg Oncol. 2016 Feb 14. Yang RL, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. J Surg Oncol. 2016 Feb. 15. Cantu E, Suzuki Y, Diamond JM, Ellis J, Tiwari J, Beduhn B, Nellen JR, Shah R, Meyer NJ, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Wilkes D, Roe D, Ware LB, Wang F, Feng R, Christie JD. Lung Transplant Outcomes Group. Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. Am J Transplant. 2015 Dec. 16. Hill C, Maxwell B, Boulate D, Haddad F, Ha R, Afshar K, Weill D, Dhillon GS. Heart- lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. Clin Transplant. 2015 Dec;29(12):1067-75. 17. Iwijn De Vlaminck, Lance Martina, Michael Kertesza, Kapil Patel, Mark Kowarskya, Calvin Strehle, Garrett Cohene, Helen Luikart, Norma F. Neff, Jennifer Okamoto, Mark R. Nicolls, David Cornfield, Weill D, Hannah Valantine, Kiran K. Khush, and Stephen R. Quake. Noninvasive monitoring of infection and rejection after lung transplantation. PNAS. 2015 Oct;112(43):13336-41. 18. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15. 19. Maxwell BG, Mooney JJ, Lee PH, Levitt JE, Chhatwani L, Nicolls MR, Zamora MR, Valentine V, Weill D, Dhillon GS. Increased resource utilization in lung transplant admissions in the Lung Allocation Score era. Am J Respir Crit Care Med. 2014 Dec 17. 20. Maxwell BG, Levitt JE, Goldstein BA, Mooney JJ, Nicolls MR, Zamora M, Valentine V, Weill D, Dhillon GS. Impact of the lung allocation score on survival beyond 1 year. Am J Transplant. 2014 Oct;14(10):2288-94. 21. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder TM, Cornfield DN, Nicolls MR, Weill D, Bernstein D, Valantine HA, Quake SR. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 2013 Nov 21;155(5):1178-87. 9|P ag e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 22. Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Bhorade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD; Lung Transplant Outcomes Group. Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. PLoS One 2012;7(12):e51932. 23. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM, Christie JD. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respi Crit Care Med 2012 Sep 15;186(6):546-52. 24. Dhillon G, Valentine V, Levitt J, Gupta M, Duncan S, Seoane L, and Weill D. Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. Clinical Transplantation. 2012 Jan-Feb;26(1):105-10. 25. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Bhorade S, Crespo M, Demissie E, Sonnett J, Wille K, Orens J, Sha PD, Weinacker A, Weill D, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belpierio JA, Wilkes D, Reynolds JM, Ware LB, Christie JD. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. Am J Transplant 2011 Nov;11(11):2517-22. 26. Liu V, Weill D., Bhattacharya J. Racial Disparities in Survival After Lung Transplantation. Arch Surg 2011 Mar;146(3):286-93. 27. Liu V, Bhattacharya J, Weill D, Hunt S, and Hlatky MA. Persistent racial disparities in survival following heart transplantation. Circulation 2011 Apr 19;123(15):1642-9. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers’ questions. 28. Weill D, Dhillon G, Freyder L, Lefante J, and Glindmeyer H. Lung function, radiologic changes, and exposure: analysis of ATSDR data from Libby, Montana. European Respiratory Journal 2011 Aug;38(2):376-83. 29. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, van der Starre P, Weill D, Nicolls MR. Lung transplant airway hypoxia: a diathesis to fibrosis. Am J Respir Crit Care Med. 2010 Jul 15;182(2):230-6. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers’ questions. 30. Deuse T, Sista R, Weill D, Haddad F, Dhillon G, Robbins RC, and Reitz BA. Review of heart-lung transplantation at Stanford. Ann Thorac Surg 2010 Jul; 90(1):329-37. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers’ questions. 31. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, and Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem. 2010 Mar 12;285(11):8196-206. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 32. Liu V, Zamora MR, Dhillon GS, and Weill D. Increasing Lung Allocation Scores Predict Worsened Survival among Lung Transplant Recipients. American Journal of Transplantation 2010 Apr;10(4):915-20. 33. Liu V, Dhillon GS, and Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010 Feb;12(1):38-44. 10 | P a g e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 34. Choi JY, Khansaheb M, Joo NS, Krouse ME, Robbins RC, Weill D, and Wine JJ. Substance P stimulates airway submucosal gland secretion mainly via a CFTR – dependent process. Journal of Clinical Investigation 2009 May;119(5):1189-200. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 35. Valentine VG, Weill D, Lombard GA, LaPlace SG, Seoane L, Taylor DE, Dhillon GS. A Single Institution Study Evaluating the Utility of Surveillance Bronchoscopy Following Lung Transplantation. Journal of Heart and Lung Transplantation 2009 Jan;28(1):14-20. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers’ questions. 36. Dhillon GS, Levitt J, Mallidi H, Valentine VG, Gupta MR, Sista R, and Weill D. Impact of Hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network for Organ Sharing database. Transplantation 2009; 88:842-846. 37. Valentine VG, Weill D, Raper B, Lombard GA, LaPlace SG, Bonvillain RW, Seoane L, Taylor DE, Dhillon GS. Ganciclovir for Cytomegalovirus: A Call for Indefinite Prophylaxis in Lung Transplantation. Journal of Heart and Lung Transplantation 2008 Aug;27(8):875-81. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers’ questions. 38. Leung M, Rachakonda L, Weill D, and Hwang P. Outcomes of Sinus Surgery before Lung Transplantation for Cystic Fibrosis. American Journal of Rhinology 2008 Mar – Apr; 22(2): 192 – 6. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 39. Mulligan MS, Shearon TH, Weill D, Pagani FD, Moore J, and Murray S. Heart and Lung Transplantation in the United States, 1997-2006. American Journal of Transplantation 2008 Apr; 8(4 Pt 2):977-87. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers’ questions. 40. Astor TL, Weill D, Cool C, Teitlebaum I, Schwarz MI and Zamora MR. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. Journal of Heart and Lung Transplantation 2005; 24:2091-7. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers’ questions. 41. Christie JD, Carby M, Bag R, Corris P, Hertz M, and Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation 2005 Oct; 24(10):1454-9. 42. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor TL, Grazia T, and Weill D. Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation. American Journal of Transplantation 2004 Oct; 4(10):1635-42. 43. Dransfield MT, Garver RI, and Weill D. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. Journal of Heart and Lung Transplantation 2004; 23(1):110-4. 44. Zorn GL, McGiffin DC, Young KR, Alexander CB, Weill D, and Kirklin JK. 11 | P a g e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 Pulmonary transplantation for advanced bronchioloalveolar carcinoma. Journal of Thoracic and Cardiovascular Surgery 2003; 125(1):45-8. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 45. Weill D, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, and McGifffin DC. Combination prophylaxis with ganciclovir and cytomegalovirus immune globulin after lung transplantation: Effective CMV prevention following daclizumab induction. American Journal of Transplantation 2003; 3(4):492-496. 46. Weill D, Dey GC, Hicks RA, Young KR, Zorn GL, Kirklin JK, Early L, and McGiffin DC. A positive donor gram stain does not predict outcome following lung transplantation. Journal of Heart and Lung Transplantation 2002; 21(5):555-8. 47. Schmidt F, McGiffin DC, Zorn G, Young KY, Weill D, and Kirklin JK. Management of congenital abnormalities of the donor lung. Annals of Thoracic Surgery 2001; 72(3):935-7. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 48. Nemunaitis J, Swisher SG, Mack M, Weill D, Merritt J, and Roth J. Adenovirus- mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non- small cell lung cancer. Journal of Clinical Oncology 2000; 18(3):609-622. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 49. Weill D, Mack MJ, Roth J, Swisher S, Proksch, Merritt J, and Nemunaitis J. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. Chest 2000; 118:966-70. 50. Weill D, McGiffin DC, Zorn GL, Alexander CB, Early LJ, Kirklin JK, and Young KR. The utility of open lung biopsy following lung transplantation. Journal of Heart and Lung Transplantation 2000; 19(9):852-857. 51. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, and Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non- small-cell lung cancer. J Natl Cancer Inst. 1999 May 5; 91(9):763-71. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 52. Weill D, Hodges TN, Torres F, and Zamora MR. Acute native lung hyperinflation is not associated with a poor outcome following single lung transplantation for emphysema. Journal of Heart and Lung Transplantation 1999; 18:1080-1087. 53. Badesch DB, Zamora MR, Weill D, and Schwarz MI. Pulmonary capillaritis: a possible histologic form of acute allograft rejection. Journal of Heart and Lung Transplantation 1998; 17(4):415-422. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 54. Terada LS, Hybertson BM, Weill D, and Repine JE. XO increases neutrophil adherence to endothelial cells by a dual mechanism. Journal of Applied Physiology 1997; 82(3):866-873. My role is this study was to provide technical support in the experimental model for the more senior researchers. My secondary role was to write the sections regarding the scientific methodology. 55. Beaver TM, Fullerton DA, Weill D, and Grover FL. Colon perforation after lung 12 | P a g e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 transplantation. Annals of Thoracic Surgery 1996; 62:839-843. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript. 56. Leard Lorriana, Holm Are, Valapour Maryam, Glanville Allan, Attawar Sandeep, Aversa Meghan, Campos Silvia, Christon Lillian, Cypel Marcelo, Dellgren Goran, Hartwig Matthew, Kapnadak Siddhartha, Kolaitis Nicholas, Kotloff Robert, Patterson Caroline, Shlobin Oksana, Smith Patrick, Sole Amparo, Solomon Melinda, Weill D, Wijsenbeek Marlies, Willemse Brigitte, Arcasoy Selim, Ramos Kathleen. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation, The Journal of Heart and Lung Transplantation, Volume 40, Issue 11, P1349-1379. November 1, 2021. Editorials 1. Weill D. Access to Lung Transplantation: The Long and Short of It. Am J Respir Crit Care Med. 2016 Mar 15;193(6):605-6. 2. Weill D. Twenty years of lung transplantation: areas of improvements and challenges. Minerva Pneumologica 2003; 42:139-57. 3. Weill D. Donor criteria in lung transplantation: an issue revisited. Chest 2002; 121:2029- 2031. 4. Weill D and Keshavjee S. Lung Transplantation for Emphysema: Two Lungs or One? Journal of Heart and Lung Transplantation 2001; 20(7):739-742. 5. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transplant Infectious Disease 2001 Suppl 2:3:44-48. Reviews 1. Galbraith D and Weill D. Popcorn Lung and Bronchiolitis Obliterans: A Critical Appraisal. International Archives and Environmental Health 2008 June 12. 2. Astor TL and Weill D. Extracorporeal photopheresis in lung transplantation. Journal of Cutaneous Medicine and Surgery 2003 Sep 9. 3. Weill D, Mack MJ, and Tennison D. Adverse effects of medications commonly administered to thoracic surgical patients. Chest Surgery Clinics of North America, Medical Complications of Thoracic Surgery, August 1999. Book Chapters/Monographs 1. Weill D. The history of lung transplantation. The Psychosocial Care of the End-Stage Disease and Transplant Patients. Editors: Sher and Maldonado, 2018. 2. Weill D. Lung transplantation: indications and contraindications. Lung Transplantation in the Third Millennium. Editors: Van Raemdonck and Venuta, 2018. 3. Dhillon GS and Weill D. Recipient management before transplantation. Lung Transplantation: Principles and Practice. Editors: Vigneswaran and Garrity, 2016. 4. Weill D. Asbestos and asbestos-related diseases. Hunter’s Diseases of Occupation, 10th 13 | P a g e FILED: ERIE COUNTY CLERK 03/03/2023 03:51 PM INDEX NO. 815818/2020 NYSCEF DOC. NO. 121 RECEIVED NYSCEF: 03/03/2023 CURRICULUM VITAE: DAVID WEILL 7 April 2022 Edition, Editors: Baxter, Aw, Cockcroft, Durrington, and Harrington, 2010. 5. Weill D. The Clinical Aspects of the Asbestos Associated Diseases. Asbestos and Its Diseases, 1st Edition, Editors: Craighead and Gibbs, 2008. 6. Astor TL and Weill D. Oxidative Lung Injury. Textbook of Critical Care, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005. 7. Weill D. Lung Transplantation. Textbook of Critical Care, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005. 8. Weill D, Rose C, and King TE. Treatment and prognosis of hypersensitivity pneumonitis. UPTODATE in Pulmonary and Critical Care Medicine, 1997, American Thoracic Society. 9. Weill D and Zamora MR. Postoperative care in lung transplantation. Seminars in Respiratory Medicine 1996; 17(2):159-165. 10. Weill D and Make B. Oxygen Conserving Devices. Long-Term Oxygen Therapy, New York: Marcel Dekker, 1994; 234-256. Letters 1. Weill D, Chatfield E, Cox A Jr, Gamble J, Gibbs G, Wylie A. In reference to Hwang et al. “The Relationship Between Various Exposure Metrics for Elongate Mineral Particles (EMP) in the Taconite Mining and Processing Industry” J Occup Envir Hyg. 2015 Jan 23. 2. Galbraith DA and Weill D. Authors’ response to Kreiss et al. Int Arch Occup Environ Health 2010 Feb;83(2):237-40. 3. Finley BL, Galbraith DA, and Weill D. Comments on respiratory toxicity of diacetyl. Toxicol SCi 2008 Oct;105(2):429-32. 4. Galbraith DA and Weill D. Diacetyl and bronchiolitis obliterans. Am J Respir Crit Care Med 2008 Aug 1;178(3):313. 5. Weill D and Weill H. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2005 Mar 1; 171(5):527-528. 6. Weill D and Zamora MR. Comparison of the efficacy and cost effectiveness of preemptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. Journal of Heart and Lung Transplantation 2000; 19(8):815-6. Oral Presentations (competitive) 1. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, Van der Starre P, Weill D, Nicolls MR. Lung Transplant Airway Hypoxia: A Diathesis to Fibrosis? American Thoracic Society Annual Meeting, New Orleans, May 2010. 2. Weill D, Young R, and McGiffin DC. A Positive Donor Gram Stain Does Not Predict the Development of Pneumonia, Oxygenation, or Duration of Mechanical Ventilation Following Lung Transplantation, International Society of Heart and Lung Transplantation, April, 2001. 3. Weill D, Young R, And McGiffin DC. The Utility of Open Lung Biopsy Following Lung Transplantation, 4th International Congress on Lung Transplantation, September, 2000. 4. Weill D, Magee M, Dewey T, and Mack MJ. Impact of